louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00221858: Regional Anesthesia Database
Official title: Regional Anesthesia Database
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Regional Anesthesia
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2005-09-22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: OTHER

Brief summary: This is a quality assurance database to prospectively examine regional anesthesia outcomes at Toronto Western Hospital.


Eligibility criteria: Inclusion Criteria:Patients having regional anesthesia -

Exclusion Criteria:Patients not having regional anesthesia

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: University Health Network
state: Ontario
Study officials:
affiliation: University Health Network, Toronto
name: Vincent WS Chan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05211258: A Novel Portable Upper Gastrointestinal Endoscopy System
Official title: A Novel Portable Upper Gastrointestinal Endoscopy System Applied in Remote Populations: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Digestive System Disease
Diagnoses Disease
Lead sponsor: Changhai Hospital
Sponsor class: OTHER
First posted: 2022-01-27
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The application of conventional endoscopy in remote and outdoor areas lacking facilities remains challenges. Thus, the investigators developed a novel portable upper gastrointestinal endoscopy system that has the same functions as conventional endoscopy. A total of 24 participants from a medical unit on a remote island in China underwent endoscopy with the portable system between March and June 2021. The portable system packed into a suitcase is 68 × 42 × 32 cm in size, weighing less than 35 kg, and comprises a disposable sheathed system.

Detailed description: The application of conventional endoscopy in remote and outdoor areas lacking facilities remains challenges. Thus, the investigators developed a novel portable upper gastrointestinal endoscopy system that has the same functions as conventional endoscopy. A total of 24 participants from a medical unit on a remote island in China underwent endoscopy with the portable system between March and June 2021. The portable system packed into a suitcase is 68 × 42 × 32 cm in size, weighing less than 35 kg, and comprises a disposable sheathed system. The examination time and any malfunctions in the portable endoscopy system during the examination were recorded. After the examination was finished, the disposable sheathed system was removed, and a pressure leak test was performed to check the seal of the system. The patients were followed up within three days to confirm any adverse events such as nausea, vomiting, throat discomfort, bleeding, etc.

Eligibility criteria: Inclusion Criteria:

* Patients who underwent endoscopy examination with the portable system were aged from 18-70 years and presented with upper abdominal complaints.

Exclusion Criteria:

* The exclusion criteria were the same as the contraindications for conventional upper GI endoscopy and included latex allergy

Primary outcomes:
measure: The examination time
timeFrame: 24 hours
Secondary outcomes:
measure: adverse events
timeFrame: one week
measure: number of malfunctions of portable endoscopy system
timeFrame: 24 hours
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Changhai Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT01455558: Safety and Pharmacokinetic Comparison of Cilostazol SR and IR Formulations in Healthy Korean Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Pharmacokinetics
Lead sponsor: Severance Hospital
Sponsor class: OTHER
First posted: 2011-10-20
Enrollment: 92
Sex: ALL
Minimum age (years): 19
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study investigates safety and pharmacokinetic comparison of Pacific Pharma's PP-101 SR (test formulation) and Otsuka's Pletaal® IR (reference formulation) for single and multiple doses and food effects on Pacific Pharma's PP-101 SR in healthy volunteers.


Eligibility criteria: Inclusion Criteria:

* Healthy male or female volunteers between the ages of 19 and 55 and within 20% of their ideal body weight, without congenital abnormality or chronic disease
* Female subjects showing positive results on a serum pregnancy test before the study, and those who were of childbearing potential agreed to use one of the following medically accepted methods of contraception during the entire period of the study: abstinence, documented tubal ligation at least 1 year before enrollment in the study, documented placement of an intrauterine device with a proven failure rate of \<1% per year, or double barrier methods (a spermicide plus a male condom or female diaphragm).

Exclusion Criteria:

* History of cardiovascular, pulmonary, renal, endogenous, gastrointestinal, hematologic, neurologic or hemorrhagic disease;
* Clinically significant findings on routine laboratory (hematology, serum chemistry and urinalysis) or ECG tests;
* Use of prescription drugs in the 14 days immediately prior to starting the study that had the potential to interact with the study medication;
* Use of any substance that could induce CYP3A4 synthesis (eg, St. John's wort, other herbal medications).

Primary outcomes:
measure: Profile of Pharmacokinetics
timeFrame: 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hours post-dose for test drug; 0, 1, 2, 3, 4, 6, 8, 10, 12, 13, 14, 15, 16, 18, 20, 22, 24, 36, 48, 72 hours post-dose for reference drug
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
Study officials:
References:
citation: Lee D, Lim LA, Jang SB, Lee YJ, Chung JY, Choi JR, Kim K, Park JW, Yoon H, Lee J, Park MS, Park K. Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study. Clin Ther. 2011 Dec;33(12):2038-53. doi: 10.1016/j.clinthera.2011.10.024. Epub 2011 Nov 29.
Clinical trial NCT05986058: Preliminary Efficacy of a Technology-based Physical Activity Intervention for Older Korean Adults During the COVID-19 Pandemic
Official title: Preliminary Efficacy of a Technology-based Physical Activity Intervention for Older Korean Adults During the COVID-19 Pandemic
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiovascular Health
Physical Function
Keywords: Physical activity intervention
Older adults
Lead sponsor: University of Illinois at Urbana-Champaign
Sponsor class: OTHER
First posted: 2023-08-14
Enrollment: 120
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study tested preliminary efficacy of a hybrid (web-based and center-based) PA intervention combining use of a smartwatch and mobile application. The 12-week hybrid PA intervention included 120 older Korean adults and was concurrently implemented in-person at the local senior center and at-home through a web-based modality. Overall, increases were evident in systolic/diastolic blood pressure, total cholesterol, and high-density-lipoprotein at posttest, with decreases seen for triglyceride levels. Participants showed improvements in muscular function and cardiopulmonary endurance.


Eligibility criteria: Inclusion Criteria:

* aged 60 and over
* enrolled member at the participating senior center for at least three years
* fluent in Korean

Exclusion Criteria:

* younger than 60 years old
* less than three years enrollment at the senior center
* cannot read and speak Korean

Primary outcomes:
measure: Cardiovascular health
timeFrame: Pre (baseline) and posttest (through study completion, 12 weeks later from the baseline)
Secondary outcomes:
measure: Physical function
timeFrame: Pre (baseline) and posttest (through study completion, 12 weeks later from the baseline)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Mokdong Senior Welfare Center
Study officials:
References:
Clinical trial NCT05044858: Ultrasound-Guided Mid-Point Transverse Process to Pleura Block for Thoracotomy Incisions
Official title: Analgesic Efficacy of Pre-emptive Ultrasound-Guided Mid-Point Transverse Process to Pleura Block for Patients Undergoing Posterolateral Thoracotomy Incisions: Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pre-emptive
Postoperative Pain
Thoracotomy
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2021-09-16
Enrollment: 70
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to investigate the analgesic efficacy of pre-emptive ultrasound-guided midpoint transverse process to pleura (MTP) block for posterolateral thoracotomy in cardiothoracic surgeries.

Detailed description: Preemptive preoperative analgesia was first proposed, over the years it has been gradually regarded as an intervention given before incision, facilitating mobilization and functional rehabilitation after surgery, reducing postoperative opioid consumption, decreasing the incidence of adverse events and improving patient satisfaction.

The Mid Transverse Process to Pleura block, described by Costach et al. involves deposition of drug midway between the transverse process and pleura. Costach et al. postulated that the local anesthetic deposited at this point may reach the paravertebral space through several possible mechanisms, such as spread medially through the gap between the superior costotransverse ligament (SCTL) and vertebral bodies, through fenestrations in SCTL, and laterally through the internal intercostal membrane

Eligibility criteria: Inclusion Criteria:

* Patients aged 21- and65 years old
* American Society of Anesthesiologists (ASA) II-III
* Scheduled for posterolateral thoracotomy operation under general anesthesia

Exclusion Criteria:

* Patients with bleeding disorders,
* Mental or cognitive dysfunction
* History of chronic analgesic or drug abuse
* Allergy to local anesthetics
* Local infection at site of block

Primary outcomes:
measure: The degree of Postoperative Pain
timeFrame: 24 hours postoperative
Secondary outcomes:
measure: The amount of Postoperative morphine consumption
timeFrame: 24 hours Postoperative
measure: Time to the first rescue analgesia request
timeFrame: 24 hours Postoperative
measure: SpO2/FiO2 ratio
timeFrame: 24 hours Postoperative
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Faculty of Medicine Tanta University
state: Elgarbia
Study officials:
References:
Clinical trial NCT02078258: Attention Bias Modification Treatment for Major Depressive Disorder in Adolescents
Official title: Attention Bias Modification Treatment for Major Depressive Disorder in Adolescents: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Major Depressive Disorder, Single Episode, Unspecified
Keywords: depression，adolescent，attention bias，modification
Lead sponsor: Hunan Normal University
Sponsor class: OTHER
First posted: 2014-03-05
Enrollment: 45
Sex: ALL
Minimum age (years): 11
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, we test whether a two-week 8-session neutral attention bias modification (ABM) training and a two-week 4-session positive ABM could reduce depressive symptoms relative to placebo controls in adolescents with major depressive disorder at posttraining and follow-ups during one year.

Detailed description: Depression is a common health problem in adolescents. Negative attentional bias has been theorized to play a critical role in the onset and maintenance of depression, suggesting that reduction of such biases may treat symptoms of depression. Recent studies have shown that attention bias modification(ABM) training could reduce depressive symptoms in both dysphoria and previously depressed adult patients.To test the effectiveness of ABM training on the treatment of depressive symptoms in depressed adolescents, we designed a randomized, double-blind, placebo controlled trial in adolescents with major depressive disorder(MDD).

Eligibility criteria: Inclusion Criteria:

* Meet the major depression disorder's criteria

Exclusion Criteria:

* bipolar disorder, schizophrenia or organic mental disorder;
* any concurrent psychotherapy;
* any concurrent psychotropic medication.

Primary outcomes:
measure: Changes in depressive symptom number
timeFrame: baseline, 7-week, 6-month follow-up
measure: Changes in depressive severity
timeFrame: baseline, 7-week, 6-month follow-up
Secondary outcomes:
measure: Change of Self-report symptoms
timeFrame: baseline, 7-week, 6-, 12-month follow-up
measure: Diagnostic status of major depressive disorder
timeFrame: baseline, 7-week, 6-month follow-up
Other outcomes:
Locations:
city: Changsha
country: China
facility: Department of Psychology, Hunan Normal University
state: Hunan
Study officials:
affiliation: Hunan Normal University
name: Wenhui Yang, Ph.D, MD.
role: STUDY_DIRECTOR
References:
citation: Yang W, Zhang JX, Ding Z, Xiao L. Attention Bias Modification Treatment for Adolescents With Major Depression: A Randomized Controlled Trial. J Am Acad Child Adolesc Psychiatry. 2016 Mar;55(3):208-18.e2. doi: 10.1016/j.jaac.2015.12.005. Epub 2015 Dec 23.
Clinical trial NCT05963958: HD-Tdcs and Pharmacological Intervention For Delirium In Critical Patients With COVID-19
Official title: HD-Tdcs Associated With The Use Of Dexmedetomidine For Delirium In Critical Patients With Covid-19
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19
Delirium
Critical Illness
Lead sponsor: Federal University of Paraíba
Sponsor class: OTHER
Collaborators: name: City University of New York
First posted: 2023-07-27
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial Is conducted to evaluate the efficacy and safety of active or sham HD-tDCS in combination with dexmedetomidine in patients with moderate to severe ARDS due to COVID-19 with delirium in intensive care unit (ICU). The hypothesis was that HD-tDCS combined with concomitant dexmedetomidine would reduce delirium rates.


Eligibility criteria: Inclusion Criteria:

* age ≥18 years,
* confirmed clinical diagnosis for SARS-CoV-2,
* delirium confirmed through the CAM-ICU-7 test, applied by trained evaluators

Exclusion Criteria:

* severe psychiatric illness that is not well controlled;
* pregnancy or active lactation,
* refusal of consent
* contraindications for brain stimulation such as: aneurysm clips, pacemaker, epilepsy, dermatitis at the site of stimulation

Primary outcomes:
measure: Delirium Severity
timeFrame: 28 days
Secondary outcomes:
measure: length of stay in the ICU and hospital stay
timeFrame: 28 days
measure: Occurrence of hypotension requiring any vasopressor administration
timeFrame: 28 days
measure: C-reactive protein levels
timeFrame: 28 days
measure: ventilator-free days during the first 28 days
timeFrame: 28 days
measure: Exploratory analisys
timeFrame: 28 days
Other outcomes:
Locations:
city: João Pessoa
country: Brazil
facility: Federal University of Paraiba
state: Paraiba
Study officials:
References:
Clinical trial NCT03661658: Inferior Alveolar Nerve Lateralization With Simultaneous Implant Placement Versus the Use of Short Dental Implants
Official title: Inferior Alveolar Nerve Lateralization With Simultaneous Implant Placement Versus the Use of Short Dental Implants
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Primary Stability of the Implants
Marginal Bone Loss
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-09-07
Enrollment: 8
Sex: ALL
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Assess the long term stability of short dental implants in comparison to standard implants inserted simultaneously with inferior alveolar nerve lateralization.


Eligibility criteria: Inclusion Criteria:

* Adult patients with edentulous posterior mandible.
* Both sexes.
* No intraoral soft and hard tissue pathology.
* No systemic condition that contraindicate implant placement.
* Residual alveolar bone width longer than 6 mm height (7-9 mm).

Exclusion Criteria:

* Presence of fenestrations or dehiscence of the residual ridge.
* Heavy smokers more than 20 cigarettes per day .(24)
* Patients with systemic disease that may affect normal healing.
* Psychiatric problems
* Disorders to implant are related to history of radiation therapy to the head and neck neoplasia, or bone augmentation to implant site.

Primary outcomes:
measure: Primary stability
timeFrame: 3 months
Secondary outcomes:
measure: Marginal bone loss
timeFrame: 3 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ehab Ahmed Shams
Study officials:
References:
Clinical trial NCT00522158: Effects of Achieving Very Low LDL-Cholesterol After Treatment With Statins on Steroidogenesis and Cognition
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Type 2 Diabetes Mellitus
Cardiovascular Disease
LDL Cholesterol
Cognition
Lead sponsor: Baskent University
Sponsor class: OTHER
First posted: 2007-08-29
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: We aimed to compare the effect of achieving an LDL-cholesterol \<70 vs an LDL-cholesterol \<100 mg/dL with simvastatin or atorvastatin on adrenal and testicular steroidogenesis, and cognition in diabetic patients.


Eligibility criteria: Inclusion Criteria:

* patients with controlled type 2 diabetes mellitus with overt CVD
* patients with controlled type 2 diabetes mellitus over the age of 40 years without overt CVD,but with one or more major cardiovascular risk factors

Exclusion Criteria:

* uncontrolled hypertension (systolic blood pressure \>180 mm Hg or diastolic blood pressure \>95 mm Hg); evidence of active active liver disease or hepatic dysfunction defined as a level of liver transaminases \>2 times the upper limit of normal; uncontrolled myocardial ischaemia; congestive heart failure (New York Heart Association classification IIIb or IV); hemodynamically important valvular disease; secondary hypercholesterolemia; gastrointestinal disease that might limit drug absorption or partial ileal bypass; myopathy, or rhabdomyolysis; a known hypersensitivity to statins; using any androgenic, estrogenic, progestogenic, antiandrogenic, or antiestrogenic agents or medications that can alter the gonadal steroid milieu; using systemic immunosuppressants or anticoagulants; plasma creatine kinase levels \>50% above the upper limit of normal,transient ischaemic attack or stroke in past,severe hypertriglyceridaemia (fasting triglyceride level ≥350 mg/dl,Currently on psychotropic medications, steroids, opiate analgesics, Known case of major neuropsychiatric illness,Poor cognition at baseline \[Mini-Mental State Examination(MMSE) score ≤24\],Physically or mentally unable to complete tests, history of other risk factors for hearing loss and/or conventional assessment that presented conductive hearing loss, confirmed by acoustic immittance measurement;presence of non-auditory associated disorders that could lead to long-latency potentials, such as neurological diseases or syndromes

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Baskent University Faculty of Medicine
name: Zehra Berberoglu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05384158: Valuation in Depressed Mood, Anhedonia, and Anxiety
Official title: Evaluating Overlap and Distinctiveness in Neurocomputational Loss and Reward Elements of the RDoC Matrix
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Neurobehavioral Components of Reward and Loss Valuation
Keywords: depression
anxiety
anhedonia
Lead sponsor: Virginia Polytechnic Institute and State University
Sponsor class: OTHER
First posted: 2022-05-20
Enrollment: 252
Sex: ALL
Minimum age (years): 25
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study examines how people respond to rewards and losses, and the extent to which these responses are linked or distinct among people experiencing depressed mood, anhedonia, and/or anxiety.

Detailed description: This study tests relationships among neural and behavioral valuation mechanisms, and how these mechanisms change (or not) over time, with task instructions, and following cognitive behavior therapy.

Eligibility criteria: Inclusion Criteria:

* mood, anxiety, or anhedonia symptoms that affect functioning; fluent in English; able to see computer display; able to perform simple computer games.

Exclusion Criteria:

* history of seizure disorder, stroke, or head injury with more than 10 minutes of unconsciousness; hormone disorder; electroconvulsive therapy within 5 years; history of chemotherapy for cancer; current pregnancy; contraindications to MRI

Primary outcomes:
measure: change in proportion correct on the 'N-arm bandit learning task'
timeFrame: study entrance to study exit, an average of 12 weeks
Secondary outcomes:
measure: change in depression symptoms (Beck Depression Inventory)
timeFrame: study entrance to exit, an average of 12 weeks
measure: change in anxiety symptoms (anxiety subscale; Mood and Anxiety Symptom Questionnaire)
timeFrame: study entrance to exit, an average of 12 weeks
measure: change in anhedonia symptoms (anhedonia subscale; Mood and Anxiety Symptom Questionnaire)
timeFrame: study entrance to exit, an average of 12 weeks
Other outcomes:
Locations:
city: Roanoke
country: United States
facility: Fralin Biomedical Research Institute at Virginia Tech Carilion
state: Virginia
Study officials:
References: